Welcome to Foundation Medicine

Foundation Medicine is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

Our portfolio of genomic profiling services

High-quality portfolio

Foundation Medicine: An established portfolio of services for patients across diverse clinical situations

Foundation Medicine’s established portfolio of comprehensive genomic profiling (CGP) services should be used to inform the use of immunotherapies, identify alternative therapy options or identify trial opportunities:1–7
EXPLORE EXPLORE Solid tumour What type of tumour does your patient have? Tissue sample Blood sample Tissue-based test for solid tumours 8 Liquid biopsy test for solid tumours 9
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine’s services use our CGP approach, which analyses the tumour genome to identify clinically relevant alterations and inform treatment decision-making.1–7
Genomic database

 

Our tests evolve as our understanding of cancer broadens

Our continuously growing genomic database currently includes over 200,000 genomic profiles in over 150 common and rare tumour subtypes.10 Advanced bioinformatics interpret the data, including rare and complex alterations, to generate potentially actionable insights.10 Our tests are regularly refined to continue to capture clinically relevant genomic alterations, so that you stay up-to-date and have confidence that the latest treatment options have been considered.

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights

RXUKRFMI00099 November 2019
References
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  3. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  4. Ross JS et al. Cancer 2016; 122: 2654–2662.
  5. Suh JH et al. Oncologist 2016; 21: 684–691.
  6. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  7. Clark TA, et al. J Mol Diagn. 2018;20:686–702.
  8. FoundationOne® CDx Technical Specifications. Last accessed November 2019.
  9. FoundationOne® Liquid Technical Specifications. Last accessed November 2019.
  10. FoundationCore™. FoundationInsights™. Available at https://www.foundationmedicine.com/insights-and-trials/foundation-insights. Last accessed November 2019.